An Analysis of Bevacizumab or Cetuximab for CRC

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 2)
Volume 2
Issue 1

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Read more about the treatment of CRC > >

Articles in this issue
Bevacizumab, Cetuximab Show Similar Benefit as First-Line Therapy in mCRC
Bevacizumab, Cetuximab Show Similar Benefit as First-Line Therapy in mCRC
An Analysis of Bevacizumab or Cetuximab for CRC
An Analysis of Bevacizumab or Cetuximab for CRC
The Importance of Testing for BRAF Status in CRC Patients
The Importance of Testing for BRAF Status in CRC Patients
Proactive Management of Regorafenib-Associated AEs
Proactive Management of Regorafenib-Associated AEs
Significant OS Benefit Seen With TAS-102 Monotherapy in Refractory mCRC
Significant OS Benefit Seen With TAS-102 Monotherapy in Refractory mCRC
Survival Benefit Confirmed With Palliative Resection in mCRC
Survival Benefit Confirmed With Palliative Resection in mCRC
Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC
Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC
Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
To Detect More Alterations, Consider Adding Companion Testing to NGS

To Detect More Alterations, Consider Adding Companion Testing to NGS

April 19th 2024
Article

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Shift to Value-Based Care Brings New Desires for EHR Capabilities

Shift to Value-Based Care Brings New Desires for EHR Capabilities

April 18th 2024
Article

A survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

The Myeloma Trial Result I Did Not See Coming

The Myeloma Trial Result I Did Not See Coming

April 17th 2024
Article

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

Read More

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

April 17th 2024
Article

During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.

Read More